Prescribe Thiopurine drugs?

The thiopurine drugs are widely used to treat. However, the incidence of adverse reactions is high, particularly in Asia.
NUDT15 genotyping is a good candidate for predicting thiopurine toxicity in East Asian populations. (Kakuta et al. 2018)

MEBRIGHT™ NUDT15 Kit

Nudix hydrolase 15 (NUDT15) genetic polymorphism kit

• Predict risks of serious adverse events from thiopurine drugs*.
• Detect the NUDT15 codon 139 genetic polymorphism by RT-PCR.
• Useful support in selecting treatment options for patients with reduced NUDT15 activities.
• Approved as IVD by PMDA** in Japan.

*Thiopurine drugs are used to treat patients such as SLE, IBD and Behcet's disease.
**PMDA: Pharmaceuticals and Medical Devices Agency

Request documents

Contact Us

MEBRIGHT™ NUDT15 Kit

is a reagent for assessing three types of alleles by detecting genetic polymorphism at codon 139 of the NUDT15 gene. The kit adopts the real-time PCR method and uses genome DNAs extracted from whole blood as specimens. The kit allows to predict patients with a high risk of serious adverse events from thiopurine drugs and provides support in selecting treatment options for those with reduced NUDT15 activities.

[ Polymorphisms detected with MEBRIGHT™ NUDT15 Kit ]

[ Associations in NUDT15 codon139 genotypes between MEBRIGHT™ NUDT15 Kit and severe adverse events ]

Detection results of this product and the incidence rate of side effects due to thiopurine-type immunoregulatory agents.

Reference

Kakuta et al. (2018). "Pharmacogenetics of thiopurines for inflammatory bowel disease in East Asia: prospects for clinical application of NUDT15 genotyping." Journal of Gastroenterology 53(2): 172-180.

MEBRIGHT™ is a registered trademark of Medical & Biological Laboratories Co., Ltd.

Products may not be approved for sale as in vitro diagnostics in all countries. Please contact us for further details.

Request documents

Please feel free to ask us!